Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade D 136.45 1.07% 1.45
BGNE closed down 0.73 percent on Monday, March 18, 2019, on 52 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical BGNE trend table...

Date Alert Name Type % Chg
Mar 18 Fell Below 50 DMA Bearish 1.07%
Mar 18 MACD Bearish Centerline Cross Bearish 1.07%
Mar 18 Hammer Candlestick Bullish 1.07%
Mar 15 20 DMA Resistance Bearish 0.34%
Mar 15 Shooting Star Candlestick Bearish 0.34%
Mar 15 Crossed Above 50 DMA Bullish 0.34%
Mar 15 Pocket Pivot Bullish Swing Setup 0.34%
Mar 14 Fell Below 50 DMA Bearish 1.24%
Mar 14 180 Bearish Setup Bearish Swing Setup 1.24%
Mar 14 Narrow Range Bar Range Contraction 1.24%

Older signals for BGNE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Oncogenes Humanized Antibody Lymphomas Ras Subfamily Braf Kras
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 220.1
52 Week Low 105.19
Average Volume 318,328
200-Day Moving Average 150.0458
50-Day Moving Average 136.0448
20-Day Moving Average 139.42
10-Day Moving Average 137.43
Average True Range 6.099
ADX 12.68
+DI 22.349
-DI 30.3141
Chandelier Exit (Long, 3 ATRs ) 136.703
Chandelier Exit (Short, 3 ATRs ) 146.417
Upper Bollinger Band 150.6618
Lower Bollinger Band 128.1782
Percent B (%b) 0.3
BandWidth 16.126524
MACD Line -0.0846
MACD Signal Line 0.8972
MACD Histogram -0.9818
Fundamentals Value
Market Cap 5.38 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -27.16
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 140.75
Resistance 3 (R3) 140.47 138.29 139.79
Resistance 2 (R2) 138.29 136.82 138.42 139.47
Resistance 1 (R1) 136.64 135.92 135.55 136.92 139.15
Pivot Point 134.46 134.46 133.91 134.59 134.46
Support 1 (S1) 132.81 132.99 131.72 133.09 130.85
Support 2 (S2) 130.63 132.09 130.76 130.53
Support 3 (S3) 128.98 130.63 130.21
Support 4 (S4) 129.26